Aimmune Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2011-01-01

Employees: 275

Market Cap: -

Website: http://www.aimmune.com

Clinical Trials

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Phase 2

Terminated

Conditions: Hen Egg Allergy

Interventions: Biological: AR201 powder
Biological: Placebo powder

First Posted Date: 2019-08-14

Last Posted Date: 2022-03-10

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 15

Registration Number: NCT04056299

Locations: 🇺🇸
Peninsula Research Associates, Rolling Hills Estates, California, United States
🇺🇸
Allergy & Asthma Medical Group and Research Center, A.P.C, San Diego, California, United States
🇺🇸
Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States

and more 8 locations

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101 powder provided in capsules & sachets
Biological: Placebo powder provided in capsules & sachets

First Posted Date: 2018-11-09

Last Posted Date: 2023-03-02

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 146

Registration Number: NCT03736447

Locations: 🇺🇸
Children's Center for Advanced Pediatrics Clinical Research Lab, Atlanta, Georgia, United States
🇺🇸
Atlanta Allergy & Asthma Clinic, Marietta, Georgia, United States
🇺🇸
Atlantic Research Center, Ocean City, New Jersey, United States

and more 20 locations

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Phase 3

Terminated

Conditions: Peanut Allergy

Interventions: Biological: AR101

First Posted Date: 2018-10-12

Last Posted Date: 2021-07-13

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 1

Registration Number: NCT03703791

Locations: 🇪🇸
Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain
🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain

and more 8 locations

AR101 Real-World Open-Label Extension Study

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101

First Posted Date: 2017-11-09

Last Posted Date: 2021-11-02

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 243

Registration Number: NCT03337542

Locations: 🇺🇸
Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
🇺🇸
Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 57 locations

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101

First Posted Date: 2017-09-25

Last Posted Date: 2024-12-19

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 911

Registration Number: NCT03292484

Locations: 🇺🇸
Jonathan Corren, M.D., Inc., Los Angeles, California, United States
🇺🇸
Chesapeake Clinical Research, Inc., Baltimore, Maryland, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 90 locations

ARTEMIS Peanut Allergy In Children

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101 powder provided in capsules & sachets
Other: Placebo powder provided in capsules & sachets

First Posted Date: 2017-06-28

Last Posted Date: 2021-08-03

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 175

Registration Number: NCT03201003

Locations: 🇫🇷
Hopital Saint Vincent de Paul, Service d'Allergologie, Lille Cedex, France
🇫🇷
Unité de dermatologie Pédiatrique, Hôpital Pellegrin-Enfants, place Amélie Raba-Léon, Bordeaux Cedex, France
🇫🇷
Paediatric Allergy and Pulmonology Center, Jeanne de Flandre Hospital, Lille University Hospital, Lille cedex, France

and more 15 locations

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: Placebo
Biological: AR101

First Posted Date: 2017-04-24

Last Posted Date: 2021-11-02

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 506

Registration Number: NCT03126227

Locations: 🇺🇸
Children's Hospital Los Angeles, Division of Clinical Immunology and Allergy, Los Angeles, California, United States
🇺🇸
Sean N. Parker Center for Allergy Research, LPCH at El Camino Hospital, Mountain View, California, United States
🇺🇸
UCLA Medical Center, Santa Monica, Santa Monica, California, United States

and more 64 locations

PALISADE Follow-on Study (ARC004)

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101

First Posted Date: 2016-12-15

Last Posted Date: 2022-03-17

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 388

Registration Number: NCT02993107

Locations: 🇺🇸
Sean N. Parker Center for Allergy Research at Stanford University Packard-El Camino Hospital, Mountain View, California, United States
🇺🇸
Atlanta Allergy & Asthma Clinic, PA, Marietta, Georgia, United States
🇨🇦
Cheema Research Inc., Mississauga, Ontario, Canada

and more 61 locations

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Phase 3

Completed

Conditions: Peanut Allergy

Interventions: Biological: Placebo powder provided in capsules & sachets
Biological: AR101 powder provided in capsules & sachets

First Posted Date: 2015-12-21

Last Posted Date: 2022-03-17

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 555

Registration Number: NCT02635776

Locations: 🇺🇸
UCLA Medical Center, Santa Monica, Los Angeles, California, United States
🇺🇸
Sean N. Parker Center for Allergy Research, LPCH at El Camino Hospital, Mountain View, California, United States
🇺🇸
Allergy & Asthma Medical Group and Research Center, A.P.C, San Diego, California, United States

and more 66 locations

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Phase 2

Completed

Conditions: Peanut Allergy

Interventions: Biological: AR101 - Peanut protein capsule

First Posted Date: 2014-07-24

Last Posted Date: 2021-11-09

Lead Sponsor: Aimmune Therapeutics, Inc.

Target Recruit Count: 47

Registration Number: NCT02198664

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
UC San Diego, San Diego, California, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy